

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.

[Get News Alerts by Email](#)

All Years



Search

Go

[Advanced Search](#)

Apr 30 2024

[BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Apr 18 2024

[BioLife Solutions Announces the Divestiture of its Stirling Freezer Business](#)

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader...

Mar 04 2024

[BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Feb 29 2024

[BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results](#)

Fourth quarter Cell Processing revenue up 11% sequentially to \$14.8 million, and positive adjusted EBITDA of \$700,000 Expects 2024 revenue of \$95.5 - \$100.0 million excluding freezer business and...

Feb 20 2024

[BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Jan 08 2024

[BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue](#)

Fourth quarter Cell Processing revenue increased 11% sequentially to \$14.8 million BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"),...

Nov 09 2023

[BioLife Solutions Reports Third Quarter 2023 Financial Results](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene...

Nov 02 2023

[BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Oct 19 2023

[BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023](#)

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of \$33.3...

Aug 08 2023

[BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business](#)

Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2023 /PRNewswire/ -- BioLife...

Jul 27 2023

[Jun 14 2023](#)

[BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

[Jun 14 2023](#)

[BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

[Jun 06 2023](#)

[BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen \(LN2\) Controlled-Rate Freezer](#)

Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order BOTHELL, Wash., June 6, 2023 /PRNewswire/ -- BioLife Solutions, Inc....

[May 10 2023](#)

[BioLife Solutions Reports First Quarter 2023 Financial Results](#)

Revenue of \$37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022...

[May 02 2023](#)

[BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

[Mar 16 2023](#)

[BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results](#)

Record full year revenue of \$161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and...

[Mar 10 2023](#)

[BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools

and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided...

Mar 09 2023

[BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Mar 01 2023

[BioLife Solutions Launches Ultraguard™ -70°C Phase Change Material \(PCM\) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material Storage](#)

Exclusive global supplier of non-toxic, non-flammable PCM; first to operate at -70°C, meeting critical temperature requirement of biologic materials. BOTHELL, Wash., March 1, 2023 /PRNewswire/ --...

Jan 17 2023

[BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and...

Jan 10 2023

[BioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work For](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and...

Jan 09 2023

[BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance](#)

Record quarterly revenue of \$44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of \$161.9 million up 36% over 2021, with organic revenue...

Dec 19 2022

[BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023](#)

Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin,

Recurring Revenue...

Nov 21 2022

[BioLife Solutions Expands Intellectual Property Estate](#)

7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash., Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc....

Nov 17 2022

[BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and...

Nov 09 2022

[BioLife Solutions Reports Third Quarter 2022 Financial Results](#)

Record revenue of \$40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow...

Nov 02 2022

[BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Oct 11 2022

[CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market](#)

CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire/ -- CSafe,...

Oct 03 2022

[BioLife Solutions Announces COO to Retire and Join Board of Directors](#)

Roderick de Greef retirement planned for January 2023 with appointment to BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior Vice...

Aug 25 2022

[BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors](#)

Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ --...

Aug 09 2022

[BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance](#)

Record revenue of \$40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to \$160 million to...

Aug 02 2022

[BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Jun 09 2022

[BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services](#)

The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level BOTHELL, Wash., June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc....

May 09 2022

[BioLife Solutions Reports First Quarter 2022 Financial Results](#)

Revenue of \$36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of \$159.5 million to \$171.0...

May 09 2022

[BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

May 02 2022

[BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Apr 07 2022

[BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Mar 18 2022

[BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Mar 17 2022

[BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Mar 15 2022

[BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in \\$400 Million Biostorage Services Market](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided...

Mar 01 2022

[BioLife Solutions to Attend and Present at Upcoming Investor Conferences](#)

Cowen presentation is scheduled for Wednesday, March 9th from 12:50-1:30pm ET in Track 12

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Feb 28 2022

[BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results](#)

Record quarterly revenue of \$37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64%

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Feb 21 2022

[BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Jan 10 2022

[BioLife Solutions Announces Preliminary 2021 Revenue of \\$119 Million, Up 148% Over 2020](#)

Biopreservation Media Revenue of \$43 Million Increased 39% Over 2020

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced...

Jan 04 2022

[BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing](#)

Sexton Cell Processing tools and CryoStor cGMP Freeze Media Incorporated in Cell and Gene Therapy Workflows

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an...

Dec 16 2021

[UNICEF Selects Ultra-Low Temperature \(ULT\) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines](#)

Stirling Ultracold Freezers to be Used in Africa, the Middle East and South America

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Nov 17 2021

[BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Nov 15 2021

[BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies](#)

Number 200 out of 250; more than 10,000 companies profiled

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the...

Nov 11 2021

[BioLife Solutions Announces Third Quarter 2021 Financial Results](#)

Total revenue up 200% over Q3 2020; operating revenue up 27% over Q3 2020; diluted EPS 40% over Q3 2020

Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...

Nov 04 2021

[BioLife Solutions Announces Executive Management Changes](#)

BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets,...

Show per page

« 1 [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) »



<https://investors.biolifesolutions.com/press-releases?l=50&o=0>